CD163 and breast cancer: For example, although CD68+ leukocyte density alone was not found to be a prognostic biomarker in primary treatment-naive BC, a CD68Hi, CD4Hi, CD8Lo immunoprofile was associated with reduced overall survival and recurrence-free survival50, and the presence of TAMs expressing the CD163 scavenger receptor was associated with adverse prognostic features in BC51.